Two Sigma Investments LP Buys New Holdings in Pieris Pharmaceuticals Inc (PIRS)

Two Sigma Investments LP purchased a new stake in shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 59,950 shares of the biotechnology company’s stock, valued at approximately $159,000.

A number of other hedge funds have also made changes to their positions in PIRS. SG Americas Securities LLC acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $36,000. Prudential Financial Inc. acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $43,000. Alambic Investment Management L.P. acquired a new position in Pieris Pharmaceuticals during the fourth quarter valued at approximately $59,000. Rhumbline Advisers lifted its position in Pieris Pharmaceuticals by 51.5% during the fourth quarter. Rhumbline Advisers now owns 66,836 shares of the biotechnology company’s stock valued at $178,000 after buying an additional 22,720 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Pieris Pharmaceuticals by 8.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 70,498 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 5,487 shares in the last quarter. 70.73% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PIRS stock opened at $3.10 on Wednesday. The company has a market cap of $152.86 million, a price-to-earnings ratio of -6.20 and a beta of 1.88. Pieris Pharmaceuticals Inc has a fifty-two week low of $2.39 and a fifty-two week high of $6.94.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). The business had revenue of $4.91 million for the quarter, compared to analyst estimates of $6.92 million. Pieris Pharmaceuticals had a negative net margin of 91.93% and a negative return on equity of 54.54%. Equities research analysts predict that Pieris Pharmaceuticals Inc will post -0.81 EPS for the current year.

PIRS has been the topic of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Pieris Pharmaceuticals in a research report on Tuesday, March 19th. Zacks Investment Research cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, ValuEngine cut shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $4.38.

WARNING: “Two Sigma Investments LP Buys New Holdings in Pieris Pharmaceuticals Inc (PIRS)” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2019/04/17/two-sigma-investments-lp-buys-new-holdings-in-pieris-pharmaceuticals-inc-pirs.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: S&P 500 Index

Want to see what other hedge funds are holding PIRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pieris Pharmaceuticals Inc (NASDAQ:PIRS).

Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.